Pharmaceutical Monopoly Rights and Ridiculously High Prices

A recent study published in the Journal of the American Medical Association (JAMA) blamed market exclusivity or monopoly rights for the high per capita drug spending in the U.S. and ridiculously high prices. Read more here. (Source: Arlene Weintraub, Forbes, 9/1/16)

You might also be interested in:

U.S. in Line with Other Countries on Out-of-Pocket Costs March 12, 2019
HCCI: Health Spending Rises Despite Little Change in Utilization February 16, 2019
Report: Only 23% of OK’d Orphan Drugs Face Generic,… December 19, 2018
Study: U.S. Health Care Remains Highest Among Developed Countries January 10, 2019
JAMA Article Takes Look at Value-Based Drug Pricing June 6, 2018
The ‘Netflix Model’ for Drug Pricing January 24, 2019
Research Suggests Low-Cost Generics at High Risk of Shortages December 14, 2018